Literature DB >> 16238191

Is there an association between acromegaly and thyroid carcinoma? A critical review of the literature.

Glenn Siegel1, Yaron Tomer.   

Abstract

Patients with acromegaly may have higher rates of cancer, possibly due to increased plasma levels of IGF-I, which is known to promote cellular growth. While simple and multinodular goiters are more common among acromegalics, reports of thyroid carcinoma are rare, and its true incidence is unclear. Here, we review the relevant literature in the context of a case of a patient with acromegaly with persistently elevated IGF-I levels who was subsequently diagnosed with thyroid carcinoma. The incidence and potential pathophysiologic mechanisms of benign and malignant thyroid disease in acromegaly are discussed. We conclude that in acromegalic patients with persistently elevated IGF-I levels, one should ensure careful monitoring of goiter and thyroid nodules, including fine-needle aspiration of nodules that are 1 cm or larger.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16238191     DOI: 10.1080/07435800500229177

Source DB:  PubMed          Journal:  Endocr Res        ISSN: 0743-5800            Impact factor:   1.720


  11 in total

1.  Growth hormone modulation of EGF-induced PI3K-Akt pathway in mice liver.

Authors:  Ma Eugenia Díaz; Lorena González; Johanna G Miquet; Carolina S Martínez; Ana I Sotelo; Andrzej Bartke; Daniel Turyn
Journal:  Cell Signal       Date:  2011-10-14       Impact factor: 4.315

2.  Insulin-like growth factor-1 is essential to the increased mortality caused by excess growth hormone: a case of thyroid cancer and non-Hodgkin's lymphoma in a patient with pituitary acromegaly.

Authors:  A Taslipinar; E Bolu; L Kebapcilar; M Sahin; G Uckaya; M Kutlu
Journal:  Med Oncol       Date:  2008-07-29       Impact factor: 3.064

3.  Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients.

Authors:  Serkan Dogan; Aysegul Atmaca; Selcuk Dagdelen; Belkis Erbas; Tomris Erbas
Journal:  Endocrine       Date:  2013-05-14       Impact factor: 3.633

4.  Expression and significance of IGF-1 and IGF-1R in thyroid nodules.

Authors:  Ying-Jian Liu; Wei Qiang; Jing Shi; Si-Qing Lv; Mei-Ju Ji; Bing-Yin Shi
Journal:  Endocrine       Date:  2013-01-04       Impact factor: 3.633

5.  Thyroid nodules in acromegaly: The role of elastography.

Authors:  M Andrioli; M Scacchi; C Carzaniga; G Vitale; M Moro; L Poggi; L M Fatti; F Cavagnini
Journal:  J Ultrasound       Date:  2010-11-05

6.  Aryl hydrocarbon receptor interacting protein mutations seem not to associate with familial non-medullary thyroid cancer.

Authors:  A Raitila; M Georgitsi; E Bonora; M Vargiolu; K Tuppurainen; M J Mäkinen; O Vierimaa; P I Salmela; V Launonen; P Vahteristo; L A Aaltonen; G Romeo; A Karhu
Journal:  J Endocrinol Invest       Date:  2009-05       Impact factor: 4.256

7.  GH modulates hepatic epidermal growth factor signaling in the mouse.

Authors:  Lorena González; Ma Eugenia Díaz; Johanna G Miquet; Ana I Sotelo; Diego Fernández; Fernando P Dominici; Andrzej Bartke; Daniel Turyn
Journal:  J Endocrinol       Date:  2009-12-23       Impact factor: 4.286

8.  Tumorigenesis of papillary thyroid cancer is not BRAF-dependent in patients with acromegaly.

Authors:  Hee Kyung Kim; Ji Shin Lee; Min Ho Park; Jin Seong Cho; Jee Hee Yoon; Soo Jeong Kim; Ho-Cheol Kang
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

9.  Benign and malignant nodular thyroid disease in acromegaly. Is a routine thyroid ultrasound evaluation advisable?

Authors:  Jordi L Reverter; Carmen Fajardo; Eugenia Resmini; Isabel Salinas; Mireia Mora; Mariona Llatjós; Gemma Sesmilo; Ferran Rius; Irene Halperin; Susan M Webb; Veronica Ricart; Pedro Riesgo; Dídac Mauricio; Manel Puig-Domingo
Journal:  PLoS One       Date:  2014-08-15       Impact factor: 3.240

10.  Thyroid diseases in patients with acromegaly.

Authors:  Anna Maria Dąbrowska; Jerzy Stanisław Tarach; Maria Kurowska; Andrzej Nowakowski
Journal:  Arch Med Sci       Date:  2013-08-12       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.